Relmada Therapeutics, Inc. Stock News

Equities analysts forecast that Relmada Therapeutics, Inc. (NASDAQ:RLMD) will announce earnings per share of ($1.87) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Relmada Therapeutics’ earnings. The highest EPS estimate is ($1.79) and the lowest is ($1.96). Relmada Therapeutics posted earnings of ($1.28) per share during the same quarter last […]

Zacks Investment Research downgraded shares of Relmada Therapeutics (NASDAQ:RLMD) from a hold rating to a sell rating in a report issued on Wednesday morning, Zacks.com reports. According to Zacks, Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company. The Company is developing LevoCap ER, an abuse resistant, once-a-day sustained release dosage form of []

Northern Trust Corp reduced its position in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) by 3.9% in the second quarter, Holdings Channel reports. The firm owned 156,398 shares of the companys stock after selling 6,296 shares during the period. Northern Trust Corps holdings in Relmada Therapeutics were worth $5,006,000 at the end of the most recent []

Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q3 2021 Results - Earnings Call Transcript

CORAL GABLES, Fla., Oct. 4, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided

CORAL GABLES, Fla., Sept. 3, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announce

Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q2 2021 Results - Earnings Call Transcript

Relmada Therapeutics, Inc. (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street ana

SVB Leerink maintains an Outperform rating on Relmada Therapeutics Inc (NASDAQ: RLMD) shares as the Human Liability Potential study data was about "as good as we could have hoped for," with no ev

Results from a human abuse potential study with REL-1017 exceeded expectations.

The stock price of Relmada Therapeutics Inc (NASDAQ: RLMD) increased by over 37% during intraday trading. This is why it happened.

NEW YORK, July 27, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today top-li

Relmada Therapeutics Inc (NASDAQ: RLMD) has acquired the development and commercial rights to novel psilocybin and derivate program from Arbormentis LLC in all ex-Asia territories, including the

NEW YORK, July 20, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the ac

NEW YORK, June 7, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Ser